Executing a Complex Phase III Diabetes Cardiovascular Outcomes Trial in a High-Risk Population Cardiovascular outcomes trials (CVOTs) in type 2 diabetes present a unique combination of clinical, operational, and regulatory complexity, particularl...
Join Julius Clinical at American Diabetes Association’s (ADA’s) Scientific Sessions 2026 in New Orleans from June 5-8, 2026. Meet our cardiometabolic experts at the 2026 Scientific Sessions to discover how Julius Clinical supports efficient, ...
Zeist, The Netherlands – 14.05.2025 – Julius Clinical, a leading clinical Contract Research Organization (CRO) with deep therapeutic expertise in CNS and Cardiometabolic indications, today announced continued growth in bookings in these key th...
A paper published in Clinical Rheumatology from the research group of our Scientific Officer Manuel Castro Cabezas and Chief Scientific Officer Rick Grobbee indicates that patients with rheumatoid arthritis with high liver fibrosis scores are like...
Commentary by Dr. Marco Alings, MD PhD, Amphia Ziekenhuis, Breda; WCN, Utrecht; Scientific Officer at Julius ClinicalThere is a strong association between age, obesity, liver fibrosis and cardiovascular (CV) disease, particularly in the conte...
At Julius Clinical, we are collaborating with Esperion to dive deeper into the findings of the CLEAR trial outcomes. Our focus? Investigating the relationship between metabolic dysfunction-associated steatotic liver disease (MASLD) and cardiovascu...
On NOVEMBER 26th, 2024, we organised the webinar: Time to event trial designs in ALS: How useful are they? During this webinar, our speakers Ruben van Eijk, Lotte Smets, Jordi van Unnik and host Lieza Exalto explored the following topics:A...
Commentary by Dr. Marco Alings, MD PhD, Amphia Ziekenhuis, Breda; WCN, Utrecht; Scientific Officer at Julius ClinicalThe estimated prevalence of Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) in the adult population is 31% ...
Utrecht, The Netherlands, 05-02-2024GRIPonMASH, a newly founded consortium consisting of 27 European institutions and companies, has bundled resources to bring about a transformational change in the detection and treatment of Metabolic Dysfunc...
On March 12th, we organised the webinar: Getting GRIP on MASH after LITMUSDuring this webinar, our speaker and hosts explored the following topics:The usefulness of noninvasive diagnostic methods depends on the prevalence of the disease ...
"*" indicates required fields
"*" indicates required fields
P95 and Julius Clinical have merged to form a leading global, full-service clinical research organization (CRO) with integrated expertise across neuroscience, cardio-renal-metabolic, and infectious diseases and vaccines. Read more here.
